Cargando…
Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature
Treatment of acute myeloid leukemia remains a therapeutic challenge. Even in younger patients with a low rate of co-morbidities less than 50% of patients can be cured. For older patients or patients with significant co-morbidities, the situation appears even worse. In patients not eligible for inten...
Autores principales: | Wolleschak, Denise, Schalk, Enrico, Krogel, Christian, Schnoeder, Tina M, Luehr, Helga, Jentsch-Ullrich, Kathleen, Fischer, Thomas, Heidel, Florian H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686641/ https://www.ncbi.nlm.nih.gov/pubmed/23759001 http://dx.doi.org/10.1186/1756-8722-6-39 |
Ejemplares similares
-
Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
por: Vachhani, Pankit, et al.
Publicado: (2016) -
Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML
por: Schmidt, Franziska, et al.
Publicado: (2022) -
Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies
por: Kasper, S, et al.
Publicado: (2012) -
getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019) -
Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification
por: Tian, Tian, et al.
Publicado: (2019)